These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23938176)

  • 21. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amisulpride: a review of its efficacy in schizophrenia.
    Möller HJ
    Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Issues in polypharmacotherapy: focus on depression in schizophrenia.
    Dufresne RL
    Psychopharmacol Bull; 1995; 31(4):789-96. PubMed ID: 8851655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of schizoaffective disorder and schizophrenia with mood symptoms.
    Levinson DF; Umapathy C; Musthaq M
    Am J Psychiatry; 1999 Aug; 156(8):1138-48. PubMed ID: 10450252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review.
    Rao ML; Möller HJ
    Neuropsychobiology; 1994; 30(4):160-72. PubMed ID: 7862264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic-minocycline-acetylcysteine combination for positive, cognitive, and negative symptoms of schizophrenia.
    Koola MM
    Asian J Psychiatr; 2019 Feb; 40():100-102. PubMed ID: 30776665
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacological treatment of negative symptoms in schizophrenia; research and practice].
    Jiawan VC; Arends J; Slooff CJ; Knegtering H
    Tijdschr Psychiatr; 2010; 52(9):627-37. PubMed ID: 20862645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on New and Emerging Treatments for Schizophrenia.
    Gopalakrishna G; Ithman MH; Lauriello J
    Psychiatr Clin North Am; 2016 Jun; 39(2):217-38. PubMed ID: 27216901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology.
    Barnes TR;
    J Psychopharmacol; 2011 May; 25(5):567-620. PubMed ID: 21292923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New developments in the pharmacotherapy of schizophrenia.
    Fleischhacker WW
    J Neural Transm Suppl; 2003; (64):105-17. PubMed ID: 12830932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of pharmacotherapy for negative symptoms of schizophrenia.
    Hanson E; Healey K; Wolf D; Kohler C
    Curr Psychiatry Rep; 2010 Dec; 12(6):563-71. PubMed ID: 20821286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of the schizophrenia prodrome: is it presently ethical?
    Cornblatt BA; Lencz T; Kane JM
    Schizophr Res; 2001 Aug; 51(1):31-8. PubMed ID: 11479063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging Treatments in Schizophrenia: Highlights from Recent Supplementation and Prevention Trials.
    Brown HE; Roffman JL
    Harv Rev Psychiatry; 2016; 24(2):e1-7. PubMed ID: 26954600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EPA guidance on treatment of negative symptoms in schizophrenia.
    Galderisi S; Kaiser S; Bitter I; Nordentoft M; Mucci A; Sabé M; Giordano GM; Nielsen MØ; Glenthøj LB; Pezzella P; Falkai P; Dollfus S; Gaebel W
    Eur Psychiatry; 2021 Mar; 64(1):e21. PubMed ID: 33726883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.
    Marder SR; Alphs L; Anghelescu IG; Arango C; Barnes TR; Caers I; Daniel DG; Dunayevich E; Fleischhacker WW; Garibaldi G; Green MF; Harvey PD; Kahn RS; Kane JM; Keefe RS; Kinon B; Leucht S; Lindenmayer JP; Malhotra AK; Stauffer V; Umbricht D; Wesnes K; Kapur S; Rabinowitz J
    Schizophr Res; 2013 Nov; 150(2-3):328-33. PubMed ID: 24028744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trials for negative symptoms--emerging directions and unresolved issues.
    Marder SR; Rabinowitz J; Kapur S
    Schizophr Res; 2013 Nov; 150(2-3):327. PubMed ID: 24209763
    [No Abstract]   [Full Text] [Related]  

  • 40. Negative symptoms in schizophrenia--the remarkable impact of inclusion definitions in clinical trials and their consequences.
    Rabinowitz J; Werbeloff N; Caers I; Mandel FS; Stauffer V; Menard F; Kinon BJ; Kapur S
    Schizophr Res; 2013 Nov; 150(2-3):334-8. PubMed ID: 23815975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.